Autoimmune encephalitides: A broadening field of treatable conditions

Neurologist

Volumn 22, Issue 1, 2017, Pages 1-13

  Kalman, Bernadette ^a,b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Markusovszky University Teaching Hospital   (Hungary)

Author keywords

Autoimmunity; Encephalitis; Immune pathogenesis; Immune therapy

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; AMPA RECEPTOR; ANTIBODY; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE LIKE PROTEIN 6; DOPAMINE 2 RECEPTOR; GANGLIOSIDE GQ 1B ANTIBODY; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; GLYCINE RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LON5 ANTIBODY; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ALLERGIC ENCEPHALITIS; ANTIBODY DETECTION; BICKERSTAFF ENCEPHALITIS; CEREBELLAR ATAXIA; CHOREA; DYSTONIA; ENCEPHALITIS; GASTROINTESTINAL DISEASE; HODGKIN DISEASE; HUMAN; IMMUNOPATHOGENESIS; MORVAN SYNDROME; MYOKYMIA; NONHUMAN; NONREM SLEEP; OPHELIA SYNDROME; PARANEOPLASTIC NEUROPATHY; PARKINSONISM; PROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDITY AND MYOCLONUS; REM SLEEP; REVIEW; SEIZURE; SLEEP DISORDER; SLEEP DISORDERED BREATHING; STIFF MAN SYNDROME; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; IMMUNOLOGY; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PATHOPHYSIOLOGY;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; ENCEPHALITIS; HUMANS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 85010383547     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0000000000000087     Document Type: Review

References (69)

1. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338:94-114.
2. Lancaster E. The diagnosis and treatment of autoimmune encephalitis. J Clin Neurol. 2016;12:1-13.
3. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091-1098.
4. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(pt 6):1655-1667.
5. Graus F, Boronat A, Xifró X, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology. 2010;74: 857-859.
6. Kim SY, Choi SA, Ryu HW, et al. Screening autoimmune antineuronal antibodies in pediatric patients with suspected autoimmune encephalitis. J Epilepsy Res. 2014;4:55-61.
7. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30:5866-5875.
8. Planagumà J, Leypoldt F, Mannara F, et al. Human N-methyl Daspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138(pt 1):94-109.
9. Schäbitz WR, Rogalewski A, Hagemeister C, et al. HZV brainstem encephalitis triggers NMDA receptor immunoreaction. Neurology. 2014;83:2309-2311.
10. Armangue T, Moris G, Cantarín-Extremera V, et al. Spanish prospective multicentric study of autoimmunity in herpes simplex encephalitis. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology. 2015;85:1736-1743.
11. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65:424-434.
12. Höftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. 2015;84:2403-2412.
13. Marignier R, Chenevier F, Rogemond V, et al. Metabotropic glutamate receptor type 1 auto-antibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol. 2010;67:627-630.
14. Iorio R, Damato V, Mirabella M, et al. Cerebellar degeneration associated with mGluR1 auto-antibodies as a paraneoplastic manifestation of prostate adenocarcinoma. J Neuroimmunol. 2013;263:155-158.
15. Coesmans M, Smitt PA, Linden DJ, et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-auto-antibodies. Ann Neurol. 2003;53:325-336.
16. Lopez-Chiriboga AS, Komorowski L, Kümpfel T, et al. Metabotropic glutamate receptor type 1 autoimmunity: clinical features and treatment outcomes. Neurology. 2016;86:1009-1013.
17. Carr I. The Ophelia syndrome: memory loss in Hodgkin's disease. Lancet. 1982;1:844-845.
18. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011;77:1698-1701.
19. Mat A, Adler H, Merwick A, et al. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology. 2013;80:1349-1350.
20. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy- responsive form of limbic encephalitis. Brain. 2004;127: 701-712.
21. Vincent A. Autoimmune channelopathies: John Newsom-Davis's work and legacy. A summary of the Newsom-Davis Memorial Lecture 2008. J Neuroimmunol. 2008;201-202:245-249.
22. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133:2734-2748.
23. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9: 776-785.
24. Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for auto-antibodies directed against K+ channels of peripheral nerves. Ann Neurol. 1995;38:714-722.
25. Thieben MJ, Lennon VA, Boeve BF, et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004;62:1177-1182.
26. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69:892-900.
27. Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136:3151-3162.
28. Irani SR, Vincent A. The expanding spectrum of clinicallydistinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr. 2012;70:300-304.
29. Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69:303-311.
30. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67-76.
31. Guan HZ, Ren HT, Yang XZ, et al. Limbic encephalitis associated with anti-g-aminobutyric acid B receptor antibodies: a case series from China. Chin Med J (Engl). 2015;128:3023-3028.
32. Ohta K, Seki M, Dalmau J, et al. Perfusion IMP-SPECT shows reversible abnormalities in GABA(B) receptor antibody associated encephalitis with normal MRI. Brain Behav. 2011;1:70-72.
33. Boronat A, Sabater L, Saiz A, et al. GABAB receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76:795-800.
34. Ohkawa T, Satake S, Yokoi N, et al. Identification and characterization of GABA(A) receptor auto-antibodies in autoimmune encephalitis. J Neurosci. 2014;34:8151-8163.
35. Solimena M, Folli F, Denis-Donini S, et al. Auto-antibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med. 1988;318: 1012-1020.
36. Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol. 2004;61:902-904.
37. Rakocevic G, Raju R, Semino-Mora C, et al. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology. 2006;67:1068-1070.
38. Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67:470-478.
39. Ariño H, Gresa-Arribas N, Blanco Y, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol. 2014;71: 1009-1016.
40. Gresa-Arribas N, Ariño H, Martínez-Hernández E, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS One. 2015;10:e0121364.
41. Dinkel K, Meinck HM, Jury KM, et al. Inhibition of gammaaminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol. 1998;44:194-201.
42. Manto M-U, Laute M-A, Aguera M, et al. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol. 2007;61:544-551.
43. Hansen N, Grünewald B, Weishaupt A, et al. Human Stiff person syndrome IgG-containing high-titer anti-GAD65 auto-antibodies induce motor dysfunction in rats. Exp Neurol. 2013;239:202-209.
44. McKeon A, Martinez-Hernandez E, Lancaster E, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol. 2013;70:44-50.
45. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008;71:1291-1292.
46. Turner MR, Irani SR, Leite MI, et al. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology. 2011;77:439-443.
47. Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137(pt 8):2178-2192.
48. Balint B, Jarius S, Nagel S, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology. 2014;82:1521-1528.
49. Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013;73:120-128.
50. Tobin WO, Lennon VA, Komorowski L, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797-1803.
51. Stoeck K, Carstens PO, Jarius S, et al. Prednisolone and azathioprine are effective in DPPX antibody-positive autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e86.
52. Piepgras J, Hö ltje M, Michel K, et al. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology. 2015;85:890-897.
53. Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575-586.
54. Högl B, Heidbreder A, Santamaria J, et al. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385: 1590.
55. Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e136.
56. Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135(pt 11):3453-3468.
57. Ben-Pazi H, Stoner JA, Cunningham MW. Dopamine receptor auto-antibodies correlate with symptoms in Sydenham's chorea. PLoS One. 2013;8:e73516.
58. Cunningham MW, Cox CJ. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta Physiol (Oxf). 2016;216:90-100.
59. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391-404.
60. Derakhshan I. Guillain-Barré, Fisher, Bickerstaff syndromes: nature versus well established ideas. J Neurol Neurosurg Psychiatry. 2000;69:703-704.
61. Ogawara K, Kuwabara S, Yuki N. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle Nerve. 2002;26:845-849.
62. Titulaer MJ, Höftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol. 2014;75:411-428.
63. Orengo JP, Pekmezci M, Cree BA. Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody-positive encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e101.
64. McKnight K, Jiang Y, Hart Y, et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology. 2005;65:1730-1736.
65. Grau-Rivera O, Sanchez-Valle R, Saiz A, et al. Determination of neuronal antibodies in suspected and definite Creutzfeldt-Jakob disease. JAMA Neurol. 2014;71:74-78.
66. Chang T, Alexopoulos H, Pettingill P, et al. Immunization against GAD induces antibody binding to GAD-independent antigens and brainstem GABAergic neuronal loss. PLoS One. 2013;8:e72921.
67. De Blauwe SN, Santens P, Vanopdenbosch LJ. Anti-glycine receptor antibody mediated progressive encephalomyelitis with rigidity and myoclonus associated with breast cancer. Case Rep Neurol Med. 2013;2013:589154.
68. Bickerstaff ER, Cloake PC. Mesencephalitis and rhombencephalitis. Br Med J. 1951;2:77-81.
69. Wang SJ, Zhao YY, Wang QZ, et al. Pearls & Oy-sters: limbic encephalitis associated with positive anti-LGI1 and antithyroid antibodies. Neurology. 2016;86:e16-e18.